Premium
Thiazolidinediones in dermatology
Author(s) -
Boyd Alan S.
Publication year - 2007
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2007.03273.x
Subject(s) - medicine , rosiglitazone , thiazolidinedione , endocrinology , metformin , psoriasis , troglitazone , lipodystrophy , necrobiosis lipoidica , diabetes mellitus , pioglitazone , type 2 diabetes mellitus , melanoma , adipocyte , receptor , adipose tissue , type 2 diabetes , cancer research , peroxisome proliferator activated receptor , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load
Thiazolidinediones, also known as glitazones, represent a relatively new class of medication used for glycemic control in patients with type II diabetes mellitus. These drugs interact with the peroxisome proliferator‐activated receptor γ, a member of the nuclear receptor superfamily, which in turn heterodimerizes with retinoid X receptors to stimulate gene transcription. At a physiologic level, glitazones stimulate adipocyte differentiation, enhance insulin‐sensitive glucose uptake by muscle and fat cells, suppress angiogenesis, inhibit tumor cell growth, and normalize keratinocyte differentiation. They have also demonstrated the capacity to diminish inflammatory cytokine production, most notably, that of tumor necrosis factor α. Patients with such disparate conditions as psoriasis, hirsutism, melanoma, angiosarcoma, lipodystrophy, and necrobiosis lipoidica have benefited from the administration of thiazolidinediones. Clinicians should become familiar with glitazones as they are experiencing a burgeoning use among patients with non‐insulin‐dependent diabetes mellitus and have demonstrated clinical efficacy in treating certain skin conditions.